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Doblinger E, Höcherl K, Mederle K, Kattler V, Walter S, Hansen
PB, Jensen B, Castrop H. Angiotensin AT1 receptor-associated protein
Arap1 in the kidney vasculature is suppressed by angiotensin II. Am J
Physiol Renal Physiol 302: F1313–F1324, 2012. First published Febru-
ary 22, 2012; doi:10.1152/ajprenal.00620.2011.—Arap1 is a protein that
interacts with angiotensin II type 1 (AT1) receptors and facilitates
increased AT1 receptor surface expression in vitro. In the present
study, we assessed the tissue localization and regulation of Arap1 in
vivo. Arap1 was found in various mouse organs, with the highest
expression in the heart, kidney, aorta, and adrenal gland. Renal Arap1
protein was restricted to the vasculature and to glomerular mesangial
cells and was absent from tubular epithelia. A similar localization was
found in human kidneys. To test the hypothesis that angiotensin II
may control renal Arap1 expression, mice were subjected to various
conditions to alter the activity of the renin-angiotensin system. A
high-salt diet (4% NaCl, 7 days) upregulated Arap1 expression in
mice by 47% compared with controls (0.6% NaCl, P  0.03). Renal
artery stenosis (7 days) or water restriction (48 h) suppressed Arap1
levels compared with controls (64 and 62% in the clipped and
contralateral kidney, respectively; and 50% after water restriction,
P  0.01). Angiotensin II infusion (2 g·kg1·min1, 7 days)
reduced Arap1 mRNA levels compared with vehicle by 29% (P 
0.01), whereas AT1 antagonism (losartan, 30 mg·kg1·day1, 7 days)
enhanced Arap1 mRNA expression by 52% (P  0.01); changes in
mRNA were paralleled by Arap1 protein abundance. Experiments
with hydralazine and epithelial nitric oxide synthase/ mice further
suggested that Arap1 expression changed in parallel with angiotensin
II, rather than with blood pressure per se. Similar to in vivo, Arap1
mRNA and protein were suppressed by angiotensin II in a time- and
dose-dependent manner in cultured mesangial cells. In summary,
Arap1 is highly expressed in the renal vasculature, and its expression
is suppressed by angiotensin II. Thus Arap1 may serve as a local
modulator of vascular AT1 receptor function in vivo.
RAAS; renin
ANGIOTENSIN II MEDIATES THE classic effects of the renin-angio-
tensin-system through activation of angiotensin type 1 (AT1)
and type 2 (AT2) receptors (22). The AT1 receptor is thought
to account for the majority of angiotensin II-dependent effects,
including vasoconstriction, stimulation of aldosterone release,
and direct and indirect enhancement of renal Na reabsorption,
which eventually results in a rise in arterial blood pressure. In
pathophysiological settings, AT1 receptor activation is related
to the progression of fibrosis in various tissues, the develop-
ment of cardiac hypertrophy, and the initiation of vascular
remodeling. Because changes in circulating angiotensin II
levels target AT1 receptors in all accessible tissues, mecha-
nisms have evolved to allow for local regulation of angiotensin
II sensitivity. These mechanisms include local changes in AT1
receptor expression, receptor desensitization, and internaliza-
tion (4). Furthermore, AT1 receptor-associated proteins have
emerged as possible additional local modulators of AT1 recep-
tor function. Several proteins that interact with AT1 receptors
have been described (8, 12, 16, 32, 33). For example, the
angiotensin receptor-associated protein Atrap, which is highly
expressed in the proximal tubule of the kidney, acts as a
negative regulator of AT1 receptors and facilitates AT1 recep-
tor internalization (11, 12, 21). Consequently, Atrap-deficient
mice have increased arterial blood pressure and blood volume
(24). Guo et al. (16) discovered another AT1-associated pro-
tein, named Arap1 (angiotensin receptor-associated protein
1), which binds to the C-terminal domain of the AT1 receptor.
Unlike Atrap, Arap1 was shown to catalyze the recycling of the
AT1 receptor to the cell membrane in vitro (16). The in vivo
relevance of Arap1 was addressed using transgenic mouse lines
that overexpressed Arap1 in the proximal tubule under the
control of the KAP promoter (15). Arap1 transgenic mice
developed salt-sensitive and angiotensin II-dependent hyper-
tension, which was accompanied by marked kidney hypertro-
phy (15). These data suggest that Arap1 enhances AT1-depen-
dent signaling in the kidney. Although expression of Arap1 has
been demonstrated in the kidney of the rat and mouse (16), its
exact localization in rodent and human kidney is unknown.
In vitro responses to angiotensin II, e.g., vascular contrac-
tion, often display desensitization, and chronic angiotensin II
infusion in vivo can only maintain elevated blood pressure
through AT1 receptors in kidney but not in heart and vessels
(9). This differential sensitivity of the AT1 receptor could be
related to angiotensin-associated proteins.
In this study, we investigated the localization of Arap1 in the
kidney of mice and humans and hypothesized that expression
of Arap1 is regulated by angiotensin II.
Renal Arap1 expression in mice and humans was predomi-
nantly localized in the vasculature. High oral salt intake in-
creased Arap1 levels, whereas conditions such as salt restric-
tion, unilateral renal artery stenosis, and water restriction
suppressed Arap1 levels compared with controls. Similarly,
angiotensin II infusion decreased renal Arap1 expression,
whereas AT1 antagonism enhanced it. In vitro experiments
revealed that angiotensin II-dependent suppression of Arap1
expression was mediated by AT1 receptors. These data indicate
that Arap1 may serve as a local modulator of renal vascular
AT1 receptor function.
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Our data suggest that Arap1 may contribute to adaptive
changes in local AT1 receptor surface expression.
METHODS
Determination of Arap1 mRNA expression. Total RNA was isolated
from various organs of the mouse using TRIzol reagent (Invitrogen).
To localize Arap1 expression to specific zones of the kidney, mouse
and human kidney specimens were microdissected and divided into
the cortex, outer medulla outer stripe (OMOS), outer medulla inner
stripe (OMIS) and inner medulla (IM). cDNA was obtained by reverse
transcription (M-MLV-RT, Invitrogen), and real-time PCR was per-
formed for Arap1, -actin, and GAPDH using the Light-Cycler
system (Roche, Mannheim, Germany). Arap1 mRNA expression data
were normalized to -actin or GAPDH mRNA expression. The
following oligonucleotide primers were used: mouse Arap1 sense
5=-ccagaaagcgagtactataagctgc-3=; mouse Arap1 antisense 5=-cttagtg-
gaaggtgttggggttgg-3=; rat Arap1 sense 5=-ccagaaagcgagtactataagctgc-
3=; rat Arap1 antisense 5=-cttaatggaaagtgttggggttgg -3=; human Arap1
sense 5=-gtgactcctttacatggcacaac-3=; human Arap1 antisense 5=-
cttagtggaaggtgttggggttcgg-3=; mouse AT1 receptor sense 5=-agagtta-
agggccattttgcttt-3=; mouse AT1 receptor antisense 5=-tcaccagatcaagtg-
cattttga-3=; mouse and human -actin sense 5=-ccgccctaggcaccagggtg-3=;
mouse and human -actin antisense 5=-ggctggggtgttgaaggtctcaaa-3=;
mouse and human GAPDH-sense 5=-ttcattgacctcaactacat-3=; and mouse
and human GAPDH-antisense 5=-gaggggccatccacagtctt-3=.
Measurement of Arap1 protein levels by immunoblotting. Western
blotting was performed according to standard protocols. Total protein
from mouse organs was obtained by homogenization in RIPA buffer
(137 mM NaCl, 3 mM KCl, 25 mM Tris·HCl, pH 7.5, 1% NP-40,
0.5% sodium deoxycholate, 0.1% SDS) containing 0.1 M PMSF.
After centrifugation, the supernatant was stored at80°C until further
use. For the protein preparation from cultured mesangial cells, cells
were incubated in RIPA buffer containing 0.1 M PMSF for 1 h at 4°C
after washing with PBS. The cell suspensions were cleared from cell
debris by two centrifugation steps at 4°C. The supernatant was stored
at 20°C. Protein concentrations were determined by the bicin-
choninic acid method (BCA Protein assay Kit, Pierce) with BSA as a
standard. In total, 200 g of total mouse kidney protein and 25 g of
rat mesangial cell protein were loaded onto an SDS-polyacrylamide
gels and separated by electrophoresis. After blotting onto a nitrocel-
lulose membrane (Transfer-Blot Transfer Medium, Bio-Rad), nonspe-
cific binding sites were blocked by incubation in TBS buffer contain-
ing skim milk. Arap1 protein was detected by incubating with anti-
Arap1 antibody (1:500, R&D Systems) for 2 h followed by incubation
with a secondary anti-goat antibody conjugated to horseradish perox-
idase (1:2,000, donkey anti-goat IgG, Santa Cruz Biotechnology).
Using ECL Western Blotting substrate (Pierce), Arap1 protein was
visualized on X-ray film and signals densities were quantified using
Bio1D software (Vilber Lourmat).
Immunohistochemistry. Immunohistochemistry was performed on
paraffin sections of mouse and human kidneys. Anesthetized mice
were perfused with 3% paraformaldehyde through the abdominal
aorta. Organs were removed and embedded in paraffin. Sections 5 m
in width were dehydrated and unmasked by heat treatment in sodium
citrate buffer (pH 6). Rabbit anti-Arap1 IgGs (HPA040933, Atlas
Antibodies; ARP54835_P050, Aviva Systems Biology) were diluted
1:200 and 1:1,000, respectively, in 10% horse serum/1% BSA/PBS
and used together with goat anti-desmin IgG (1:100, sc-7559, Santa
Cruz Biotechnology), mouse anti--actin IgG (1:200, 1144, Immuno-
tech), goat anti-CD31 IgG (1:100, AF 3628, R&D Systems), chicken
anti-renin IgG (1:400, Davids Biotechnology), and goat anti-aqua-
porin-2 IgG (1:200, sc-9882, Santa Cruz Biotechnology), respec-
tively. After incubation with secondary antibodies (Cy2-, Cy5-,
TRITC-conjugated anti-goat, anti-rabbit, anti-chicken IgG, 1:400,
Dianova), the sections were analyzed using an Axiovert 200M micro-
scope (Zeiss). Staining without the primary antibody served as a
negative control.
Human specimens. Human kidney tissue was derived from male
patients with renal cancer who underwent radical unilateral nephrec-
tomy. All patients gave their informed written consent before partic-
ipating in the study and had not received chemotherapy or radiation
before nephrectomy. The patients were between 50 and 75 yr of age.
The use of human kidney tissue was approved by the Ethical Review
Board of Southern Denmark, approval VF 20010035. Kidneys were
removed in the Department of Urology and immediately transported
to the Department of Clinical Pathology, Odense University Hospital.
The time between organ removal and initiation of microdissection
was 15–20 min, during which the tissue was chilled. Human
tissue sections were obtained from normal kidney tissue not
affected by the tumor. Tissue was embedded in paraffin, cut in
5-m sections, and unmasked by heat treatment in sodium citrate
buffer (pH 6) (3).
Animals. For all experiments, male C57BL/6 mice were used.
Animals used in the study were between 8 and 10 wk of age. All
animal experiments were performed according to the National Insti-
Fig. 1. AT1-associated protein (Arap1) mRNA expression in various organs of
the mouse as determined by quantitative RT-PCR. Values are means  SE
expressed as relative units normalized to -actin (n  5).
Fig. 2. Arap1 mRNA expression in dissected kidney zones of the mouse.
mRNA levels were determined by quantitative RT-PCR in the cortex, outer
medulla outer stripe, outer medulla inner stripe, and inner medulla. Values are
means  SE expressed as relative units normalized to -actin (n  5).
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Fig. 3. Arap1 protein localization in the mouse renal cortex. Arap1 protein (red) was localized to the vasculature of the renal cortex (A) as indicated by overlapping
staining of smooth muscle -actin [blue (B); merged C]. Arap1 was found in vessels of various sizes including the afferent arteriole (D and E; merged F).
Costaining with an anti-renin antibody [blue (H)] showed an absence of Arap1 from juxtaglomerular cells (G; merged I). Arap1 was also expressed in the
glomerulus (J), where it colocalized with the mesangial cell marker desmin [green (K); merged L], whereas the glomerular endothelium [CD31; green (N)] lacked
Arap1 (M). O: merged. Moreover, Arap1 was not present in the endothelium of blood vessels (N; arrow) as there was no overlapping staining with CD31.
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tutes of Health Guide for the Care and Use of Laboratory Animals and
were approved by the local authorities. In one set of experiments,
male endothelial nitric oxide synthase (eNOS)/ and wild-type
mice were used (5). eNOS/ and wild-type mice were 10 wk of
age.
Animal experiments. Various experimental maneuvers were created
to assess the regulation of Arap1 expression during changes in
renin-angiotensin system (RAS) activity.
For changes in oral salt intake, a group of 6 mice received a high
[4% NaCl (wt/wt)- or low-salt diet 0.02% NaCl (wt/wt), Ssniff
Spezialdiäten, Soest, Germany] for 7 days, while a control group (n
6) obtained a standard chow [0.6% NaCl (w/w)].
For water restriction, mice were kept for 48 h without access to
water. A control group had free access to tap water (n  6 each).
For unilateral renal artery stenosis, the two-kidney-one-clip (2K1C)
model of renovascular hypertension was used to induce unilateral
renal artery stenosis. Mice were anesthetized with sevoflurane, the left
kidney was exposed, and the renal artery was dissected from the renal
vein and the surrounding tissue (n  6). A silver clip (0.11-mm inner
diameter) was placed around the renal artery. The same surgical
maneuver was performed in sham-operated mice (n 6); however, no
clip was applied (30). Kidneys were harvested after 7 days. To ensure
appropriate clip placement, arterial blood pressure was determined by
tail-cuff manometry, as described previously (25).
For chronic infusion of angiotensin II, mice were infused with
angiotensin II for 7 days via osmotic minipumps (model 1002, Alzet).
Minipumps were loaded with angiotensin II dissolved in 300 mM
NaCl and 1 mM acetic acid (2 g·min1·kg angiotensin II1, Sigma-
Aldrich). Pumps were implanted subcutaneously under sevoflurane
anesthesia (n  10). A control group received osmotic minipumps
filled with vehicle (n  10). Again, the function of the osmotic
minipump was controlled by the determination of arterial blood
pressure using tail-cuff manometry.
For angiotensin II receptor antagonism, mice received the AT1
receptor antagonist losartan (Sigma-Aldrich) dissolved in their drink-
ing water for 7 days (30 mg·kg1·day1, n  6). A control group had
free access to tap water (n  6).
For hydralazine administration, mice received hydralazine (Sigma-
Aldrich) dissolved in the drinking water for 7 days (20 mg·kg1·day1,
n  5). A control group had free access to tap water (n  5).
At the end of all experiments, the mice were euthanized, and the
kidneys were frozen in liquid nitrogen and stored at 80°C until
further processing.
In vitro experiments. To assess the mechanisms regulating Arap1
expression, studies were performed in cultured rat glomerular mesan-
gial cells (gift from Dr. Eberhardt, Johann Wolfgang Goethe-Univer-
sität, Frankfurt am Main, Germany). This cell line expresses both
Arap1 and the angiotensin receptors AT1 and AT2. The cells were
grown as described previously (27). In brief, rat glomerular mesangial
cells were cultured in RPMI 1640 (PAN Biotech) supplemented with
10% FCS, penicillin-streptomycin (100 U/ml, 100 g/ml, Biochrom),
and 0.66 U/ml Insulin (Sigma-Aldrich) at 37°C and 5% CO2. One day
before the experiments, FCS was reduced to 0.5% and penicillin-
streptomycin was omitted from the medium. To address the effect of
angiotensin II on Arap1 mRNA expression, angiotensin II was added
to the wells in final concentrations of 0, 107, 106, 105 and 104
mol/l. After various incubation times, cells were washed with PBS,
suspended in TRIzol reagent, and stored at80°C until further use. In
an additional set of experiments, the AT1 receptor antagonist losartan
or the AT2 antagonist PD123319 was added 45 min before treatment
with angiotensin II (105 mol/l), and the cells were harvested after 20
h. In further experiments, protein kinase C was activated by PMA
(Sigma-Aldrich). Unless otherwise stated, six wells of cells were
investigated for each experimental condition.
Statistics. Data are expressed as means  SE. Statistical compar-
isons were made by Student’s t-test or by ANOVA with Bonferroni
post hoc tests when necessary.
RESULTS
Localization of Arap1 expression in mice and humans. A
multiple-tissue expression analysis of Arap1 in the mouse was
performed using quantitative RT-PCR. Arap1 was found in
various organs of the mouse with the following pattern of
Fig. 4. Arap1 protein localization in the mouse
renal medulla: Arap1 in the renal medulla was
restricted to blood vessels (A) overlapping with
smooth muscle -actin (B; blue) but was absent
from aquaporin 2-positive medullary collecting
ducts [green (C); overlay D].
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intestine (Fig. 1, n  5). Arap1 mRNA expression paralleled
respective protein levels, with the greatest amount of Arap1 in
the heart (not shown). To assess the distribution pattern of
Arap1 in different zones of the kidney, Arap1 mRNA levels
were quantified for the cortex, OMOS and OMIS, and IM.
Arap1 mRNA expression in the mouse kidney was character-
ized by a corticomedullary gradient, with cortical expression
levels exceeding those of the OMOS, OMIS, and IM by 59 
4, 40  10, and 130  7%, respectively (Fig. 2, n  5).
Immunohistochemistry with two antibodies targeting different
epitopes of Arap1 revealed that Arap1 protein in the mouse
kidney was localized primarily in the vasculature, as deter-
mined by costaining with anti-smooth muscle -actin and
anti-SM22 antibodies (Fig. 3, A–D). In contrast to vascular
smooth muscle cells, there was no Arap1 expression in the
vascular endothelium, as determined by costaining with an
anti-CD31 antibody (Fig. 3, I and J). Arap1 was found in both
large arteries and small resistance vessels, including the affer-
ent arterioles. Arap1 protein was absent from renin-positive
juxtaglomerular (JG) cells (Fig. 3, E and F). In addition, we
Fig. 6. Arap1 expression after modulation of oral salt intake. Arap1 mRNA
expression in the kidneys from mice fed a low [0.02% NaCl (wt/wt)]-, standard
[0.6% NaCl (wt/wt)]-, or high-salt diet [4% NaCl (wt/wt)] for 7 days. n.s., Not
significant. Values are means  SE expressed as relative units normalized to
-actin (n  6 each).
Fig. 5. Arap1 protein localization in the hu-
man kidney. Arap1 protein was expressed in
the vasculature of the renal cortex (A) and the
medulla (B) overlapping with smooth muscle
-actin [blue (C and D), overlay E and F].
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found consistent Arap1 staining of glomeruli colocalizing with
the mesangial cell marker desmin whereas Arap1 was absent
from podocin-positive podocytes (not shown) and CD31-pos-
itive glomerular capillaries (Fig. 3J). In the renal medulla,
Arap1 expression was found in the vasa recta as determined by
costaining with anti-smooth muscle -actin, whereas no Arap1
could be detected in aquaporin-2-positive medullary collecting
ducts (Fig. 4). Similarly, no Arap1 immunostaining was ob-
served in any other segment of the tubular system of the
kidney.
In the human kidney, Arap1 mRNA could be detected in all
kidney zones, with a similar distribution pattern as is found in
the mouse kidney (not shown). Arap1 protein in the human
kidney, as detected by immunostaining, was expressed in the
vasculature, with the most intense staining in the renal cortex
(Fig. 5). Similar to the mouse, vessels of the renal cortex of
various sizes including the afferent arterioles expressed Arap1
(Fig. 5A). Unlike in mice, there was no apparent Arap1
staining in mesangial cells of the human kidney. Arap1-
positive vessels were also present in the medulla of the
human kidney (Fig. 5C).
Regulation of renal Arap1 expression in vivo. Because
Arap1 may serve as a local modulator for the RAS by promot-
ing AT1 receptor surface expression, we evaluated whether and
how Arap1 expression changed with different levels of angio-
tensin II plasma concentrations.
Variations in oral salt intake are classic modulators of RAS
activity. Thus mice received an experimental diet with high
[4% NaCl (wt/wt)], standard [0.6% NaCl (wt/wt)], or low
[0.02% NaCl (wt/wt)] salt content for 1 wk, and renal Arap1
expression was determined afterward. As shown in Fig. 6, a
high-salt diet led to upregulation of Arap1 mRNA expression
in mouse kidneys by 47  14% compared with controls (P 
0.03). Conversely, a low-salt diet decreased Arap1 expression
by 27  5% compared with a standard diet, although this
difference did not reach statistical significance (P  0.07). For
AT1 receptor mRNA expression, we found no significant
changes in abundance during the various dietary regimens
(1.27  0.22, 1.18  0.15, and 1.05  0.23 rU for the high-,
standard-, and low-salt diet, respectively; n  5).
Arap1 expression was also examined during water restric-
tion, a condition accompanied by marked activation of the
RAS. Expression of Arap1 mRNA decreased significantly after
48 h of water restriction, averaging 75  3%, 47  5%, and
28  4% of controls (free access to tap water) in the cortex,
outer medulla and IM, respectively (n  6, P  0.01) (Fig. 7).
Similar to Arap1 mRNA, Arap1 protein in the total kidney was
significantly reduced by 46  12% after water restriction
compared with controls (P  0.05, n  6) (Fig. 7).
In addition to modulating Arap1 expression, water restric-
tion also influenced AT1 receptor abundance. After 48 h of
Fig. 7. Arap1 expression after water restriction. A: Arap1 mRNA expression in
kidney zones from mice after 48 h of water restriction. Values are means SE
expressed as relative units normalized to -actin (n  6 each). B: Arap1
protein abundance as determined by immunoblotting (n  6 each). Values are
means  SE. Inset: representative blot for kidney protein.
Fig. 8. Arap1 expression after renal artery stenosis. Arap1 mRNA expression
is shown in kidneys from mice after 7 days of unilateral renal artery stenosis
[2 kidney-1 clip (2K1C) model]. Controls correspond to averaged data for both
kidneys from sham-operated mice. Values are means  SE expressed as
relative units normalized to -actin (n  6 each).
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water restriction, renal AT1 receptor mRNA abundance in
water-restricted mice increased by 35  17% compared with
controls (n  9, P  0.001). Changes in AT1 mRNA abun-
dance were paralleled by protein levels, which increased by
28  9%, as determined by immunoblotting.
Unilateral renal stenosis (2K1C, 7 days) was used in the next
experiment as a model of hemodynamic activation of the RAS.
At the end of the experiment, arterial blood pressure on the
2K1C animals had increased to 179  8 mmHg whereas blood
pressure in the sham-operated mice averaged 122  5 mmHg
(tail-cuff measurements, P  0.01). Compared with sham-
operated animals, renal artery stenosis resulted in downregu-
lation of Arap1 mRNA expression by 64  6 and 62  2% in
both the clipped and contralateral kidney, respectively (P 
0.001 vs. control) (Fig. 8).
As both water restriction and renal artery stenosis result in
increased levels of circulating angiotensin II, we also examined
the direct effect of angiotensin II on renal Arap1 expression.
Mice were chronically infused with angiotensin II via osmotic
minipumps (2 g·kg1·min1 angiotensin II, 7 days). Angio-
tensin II infusion induced marked hypertension with arterial
blood pressure levels averaging 158 2 vs. 116 2 mmHg in
Fig. 9. Expression of Arap1 in zones of the kidney
after chronic angiotensin II infusion for 7 days
(2 g·kg1·min1, n  10; A) and in the total
kidney after 7 days of AT1 receptor antagonism
(losartan, 30 mg·kg1·day1, n  6; B). Values
are means  SE expressed as relative units nor-
malized to -actin (n  10 each). Insets: Arap1
protein abundance in total kidneys after angioten-
sin II infusion and losartan, respectively.
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vehicle-infused mice (P  0.01). Compared with vehicle-
infused mice, chronic angiotensin II infusion reduced Arap1
mRNA expression by 29  1.4 and 24  8% in the cortex and
in the renal medulla (n  10, P  0.001 and P  0.003),
respectively (Fig. 8A). Changes in Arap1 mRNA levels were
accompanied by changes in total kidney Arap1 protein
(Fig. 9A, inset).
In contrast to suppression of Arap1 expression by angioten-
sin II infusion, AT1 receptor antagonism by losartan (30
mg·kg1·day1 for 7 days; n  6) resulted in an increase in
Arap1 mRNA averaging 152  15% of controls (P  0.01)
(Fig. 9B) and which was accompanied by a marked induction
of Arap1 protein abundance (Fig. 9B, inset).
In parallel with Arap1, renal cortical AT1 receptor mRNA
abundance was decreased during angiotensin II infusion (18 
2% compared with controls, n  6) (P  0.01), whereas
losartan upregulated AT1 receptor levels without reaching
levels of significance (n 6; P 0.14). Similarly, AT1 protein
tended to be reduced or increased during angiotensin II infu-
sion or losartan administration, respectively (not shown).
To assess whether Arap1 expression is directly modulated
by angiotensin II or rather by changes in arterial blood pres-
sure, mice were given the vasodilator agent hydralazine (20
mg·kg1·day1 for 7 days in the drinking water) to reduce
blood pressure and increase angiotensin II levels (6, 18).
Hydralazine reduced Arap1 mRNA expression by 28  6%
compared with vehicle-infused mice (n  5, P  0.01)
(Fig. 10A). To further address a possible correlation between
blood pressure and Arap1 expression, Arap1 expression was
determined in a model of chronic hypertension. For this pur-
pose, renal Arap1 mRNA was measured in eNOS-deficient
mice and wild-type controls. In the eNOS/ strain used in
this study, marked hypertension is accompanied by virtually
normal plasma renin concentration (5). Arap1 expression in the
kidneys of eNOS/ mice averaged 0.92  0.15 rU, not
significantly different from wild-type mice (1.10  0.19 rU, n
 5, P  0.22) (Fig. 10B).
To determine whether the regulation of Arap1 is tissue
specific, Arap1 mRNA in the heart, aorta, and adrenal gland
was determined after angiotensin II infusion. In contrast to the
kidney, Arap1 in the heart and aorta was unchanged during
angiotensin II infusion, whereas it was increased in the adrenal
gland (1.26  0.2 rU vs. 0.68  0.1 rU in controls; P  0.01;
not shown).
In summary, our in vivo experiments suggest that the ex-
pression of Arap1 in the kidney is dependent on the activity of
the RAS and that the effect of angiotensin II on Arap1 is
inhibitory.
Regulation of Arap1 expression: in vitro studies. To address
the mechanisms underlying the regulation of Arap1 expression
in vivo, we performed additional in vitro studies. As shown in
Fig. 11, angiotensin II led to a dose-dependent suppression of
Arap1 expression in cultured mesangial cells averaging 71 
4, 68  2, 44  2, and 25  2% of control after incubation for
16 h with 107, 106, 105, and 104 mmol/l angiotensin,
respectively (P  0.001 for all angiotensin II concentrations).
Maximal angiotensin II-dependent suppression of Arap1
mRNA levels was reached after 8 h of incubation (Fig. 10).
Similar to in vivo conditions, downregulation of Arap1 mRNA
expression was followed by declining Arap1 protein levels as
determined by Western blotting (Fig. 11, inset).
Downregulation of Arap1 was accompanied by a minor
reduction in AT1 receptor expression, which was largely inde-
pendent of the concentration of angiotensin II, averaging 67 
8, 80  9, 77  6, and 59  13% of controls for 107, 106,
105, and 104 mmol/l angiotensin II (P  0.05 for 107 and
104 mmol/l angiotensin II; n  6; not shown).
To determine the identity of the receptor involved in angio-
tensin II-dependent downregulation of Arap1 expression, we
evaluated the effect of the AT1 receptor antagonist losartan on
Arap1 mRNA expression in cultured mesangial cells treated
with angiotensin II. Pretreatment of mesangial cells with lo-
sartan (104 mol/l) virtually abolished the effect of angiotensin
II (105 mol/l, 20 h) on Arap1 expression, resulting in a
decrease in Arap1 mRNA expression to 96  4% of controls
(P  0.13), whereas angiotensin II in the absence of losartan
downregulated Arap1 expression to 65  4% of controls (P 
0.001) (Fig. 12). In contrast to AT1 antagonism, blockade of
AT2 receptors by PD123319 (104 mol/l) did not alter the
suppression of Arap1 expression by angiotensin II (Fig. 12).
AT1 receptor-dependent regulation of Arap1 expression was
mimicked by the PKC activator PMA. As shown in Fig. 13,
PMA (105 and 107 mmol/l) suppressed Arap1 mRNA ex-
pression to 46  8 and 52  5% of controls, respectively,
which were similar to the effects of angiotensin II (105
mmol/l) (P  0.001).
Fig. 10. A: renal expression of Arap1 after infusion of hydralazine (20
mg·kg1·day1, 7 days, n  5 each). B: renal expression of Arap1 in eNOS-
deficient mice, a model of chronic hypertension. Values are means  SE ex-
pressed as relative units normalized to -actin (n  5 each).
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Data obtained from these in vitro experiments suggest that
Arap1 expression is suppressed by angiotensin II and that this
effect is mediated by AT1 receptors.
DISCUSSION
Local changes in receptor expression, receptor internaliza-
tion/membrane trafficking, and receptor-associated proteins are
potential strategies to locally regulate the effects of the RAS.
For the AT1 receptor, accessory proteins that increase or
decrease the surface expression of the AT1 receptor and con-
sequently locally modulate angiotensin II-mediated signaling
have been described (8, 12, 16, 32, 33).
We evaluated the localization and regulation of the AT1
receptor-associated protein Arap1 in the kidney. Based on in
vitro findings, Arap1 acts as a positive regulatory protein of
AT1 receptor function (16). Thus Arap1 catalyzes the traffick-
ing of the AT1 receptor to the cell surface, which will increase
baseline AT1 surface expression and resensitize the cell after
angiotensin II exposure (16). Arap1 in the mouse was ex-
pressed in various organs, with particularly high expression
levels in the heart and kidney. This finding is in accordance
with previous observations in the rat indicating that Arap1 was
expressed predominantly in the heart, kidney, and lung (16). In
the mouse kidney, Arap1 expression was found throughout the
entire vasculature. A closer inspection of the vessels revealed
that Arap1 staining was most intense in vascular smooth
muscle cells, the site of the highest AT1 receptor density in the
kidney (14, 17, 23, 26). Although Arap1 was found along
virtually the entire renal vasculature, the renin-secreting JG
cells of the afferent arteriole lacked Arap1, as determined by
costaining with an anti-renin antibody. AT1 receptors on JG
cells mediate a direct inhibitory feedback loop on renin secre-
tion (4). Thus the absence of Arap1 from JG cells may preserve
the direct feedback loop of angiotensin II on renin secretion. In
addition to the renal vasculature, Arap1 was also expressed in
mesangial cells of the mouse. Mesangial cells highly express
AT1 receptors, and angiotensin II was shown to be involved in
mesangial cell growth and secretion of extracellular matrix
proteins, including collagens and fibronectin (1, 26).
Our localization study was performed with two independent
antibodies targeting different regions of the Arap1 protein. We
are confident that these antibodies had decent specificity, as
both antibodies independently detected a virtually identical
localization pattern.
In the human kidney, Arap1 was found in vessels of the
cortex and the medulla. The distribution pattern of Arap1 in the
kidney was highly comparable between mice and humans,
suggesting a similar functional relevance in both species. In
Fig. 11. A: dose-dependent suppression of Arap1 expres-
sion in cultured mesangial cells after 16 h of exposure to
angiotensin II. Values are means SE. B: time course of
Arap1 mRNA downregulation in the presence of angio-
tensin II (104 mol/l). Values are means SE expressed
as relative units normalized to -actin (n  6 wells for
each condition). Inset: Arap1 protein as determined by
immunoblotting after 16 h of incubation with angioten-
sin II.
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contrast to mice, Arap1 expression in mesangial cells of the
human kidney was at the detection limit, which could be due to
lower overall expression levels of Arap1 in human compared
with mouse kidney or due to the different tissue fixation
procedures.
We did not detect any Arap1 protein in the tubular system of
the kidney. At the moment, we cannot rule out that there is
some minor tubular Arap1 expression that is below the detec-
tion limit of our antibodies; however, compared with the
abundant expression of Arap1 in the renal vessels, the rele-
vance of Arap1 for modulating the function of tubular AT1
receptors is presumably limited.
In view of the regulation of AT1 receptor surface expression
by Arap1 in vitro, we next evaluated Arap1 levels during
changes in RAS activity. Changes in Arap1 expression would
constitute a measure for local adaptations of AT1 receptor
density in response to fluctuating systemic angiotensin II lev-
els.
Oral salt intake is a classic determinant of RAS activity, with
a salt-restricted diet stimulating and a high-salt diet suppress-
ing renin secretion (4). Renal Arap1 expression was dependent
on oral salt intake, although the suppression of Arap1 expres-
sion during a low-salt diet did not reach statistical significance.
It should be noted in this context, however, that the stimulation
of renin secretion in response to a low-salt diet in the mouse is
usually limited, in particular compared with what is observed
in situations like water restriction or renal hypoperfusion (4).
Consequently, water restriction resulted in a markedly more
pronounced downregulation of Arap1 levels compared with a
low-salt diet.
Similar to water restriction, renal hypoperfusion results in
augmented systemic angiotensin II levels (4). Although this
mechanism appears to be a reasonable measure to ensure
constant arterial blood pressure under normal conditions, it
also triggers the development of renovascular hypertension
when renal perfusion pressure falls below normal due to renal
artery stenosis. During experimental renal artery stenosis,
Arap1 expression was downregulated to a similar degree in
both the clipped and the contralateral kidney. Because perfu-
sion pressure is presumably low in the clipped kidney and high
in the contralateral kidney, it appears unlikely that renal per-
fusion pressure is a major determinant of Arap1 expression.
This assumption is further supported by experiments using the
vasodilator agent hydralazine. Hydralazine was shown to de-
crease arterial blood pressure and to stimulate renin secretion
(6, 18). In contrast to losartan treatment, Arap1 expression was
slightly reduced in hydralazine-treated mice, suggesting that
angiotensin II levels rather than blood pressure determined
Arap1 expression. In line with these findings, renal Arap1
expression of eNOS-deficient mice, used as a model of chronic
renin-independent hypertension (5), did not differ from wild-
type mice.
These data indicate that changes in blood pressure per se
most likely do not constitute a modulator of Arap1 in the
kidney. According to the situation of renovascular hyperten-
sion, these data rather suggest that Arap1 is regulated by a
factor that impinges on both kidneys similarly, such as angio-
tensin II.
In accordance with this hypothesis, angiotensin II infusion
markedly reduced the abundance of renal Arap1 whereas AT1
receptor antagonism stimulated Arap1 expression. Interest-
ingly, the suppression of Arap1 expression was more pro-
nounced during renal artery stenosis than during angiotensin II
infusion. Although we did not determine angiotensin II con-
centrations in the plasma of angiotensin II-infused mice, we
believe that arterial blood pressure may serve as an indirect
measure of angiotensin II levels in the circulation. Because
blood pressure in angiotensin II-infused mice was significantly
lower compared with 2K1C mice, we assume that angiotensin
II levels may have also been lower, which could account for
the differences in Arap1 expression.
A direct inhibitory effect of angiotensin II on renal Arap1
expression was further suggested by in vitro experiments using
a rat mesangial cell line. We found a dose-dependent suppres-
sion of Arap1 during exposure to angiotensin II; this effect
appeared to be mediated by AT1 receptors, as it could be
blocked by AT1 antagonism whereas AT2 blockade had no
Fig. 12. Suppression of Arap1 mRNA expression in cultured mesangial cells
by angiotensin II (105 mol/l) after preincubation with the AT1 receptor
antagonist losartan (104 mol/l) or the AT2 receptor antagonist PD123319
(104 mol/l). Values are means SE expressed as relative units normalized to
-actin (n  6 wells for each condition). *P  0.001 vs. control.
Fig. 13. Influence of the protein kinase C activator PMA on Arap1 mRNA
expression in cultured mesangial cells. Values are means  SE expressed as
relative units normalized to -actin (n  6 wells for each condition). *P 
0.01 vs. control.
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effect. Furthermore, AT1 receptor activation by angiotensin II
could be mimicked by activation of protein kinase C, a classic
intracellular signaling pathway of the AT1 receptor (22). As
Arap1 mRNA and protein expression were regulated in parallel
under all experimental conditions, it appears likely that Arap1
abundance is primarily under transcriptional control.
Expression of AT1 receptors and renal angiotensin II binding
during changes in the activity of the RAS have been addressed
in several studies. Some studies report that the overall expres-
sion of renal AT1 receptors and angiotensin II binding capacity
are reduced during a salt-restricted diet (28, 29), whereas other
studies showed that renal AT1 receptors are upregulated during
low oral salt intake (13, 36). No changes in AT1 receptor
expression were found in our experiments for the renal cortex
and medulla during variations in oral salt intake. These incon-
sistent results might be related to the fact that renal vascular
and tubular AT1 receptor expression is regulated inversely
during changes in oral salt intake, which may limit net changes
in receptor abundance (7, 28). For chronic angiotensin II
infusion, no change in total renal AT1 receptor expression was
reported, whereas radio-labeled angiotensin II binding was
reduced (31). According to our data, reduced expression of
Arap1 during angiotensin II infusion may contribute to this
apparent reduction in AT1 receptor surface expression.
AT1 receptor expression in our settings of angiotensin II
infusion was slightly reduced in the cortex but unchanged in
the medulla of the kidney. Congruent with these results, a
downregulation of glomerular AT1 receptors during angioten-
sin II infusion has been shown for the rat (19).
In contrast to the renal vasculature, no Arap1 expression was
found in tubular epithelia; however, the tubular system, and
particularly the proximal tubule (the main site of tubular AT1
receptor expression) (20), expresses another angiotensin recep-
tor-associated protein called Atrap (12). Unlike Arap1, Atrap
has been shown to facilitate the internalization of the AT1
receptor and, consequently, may act as a negative local mod-
ulator of the AT1 receptor (2, 11, 21). Similar to Arap1, Atrap
is downregulated under conditions of elevated angiotensin II
levels (34, 35). As a consequence, when the kidney is exposed
to increased angiotensin II, reduced expression of both vascu-
lar Arap1 and tubular Atrap would desensitize the renal vas-
culature and concomitantly sensitize the proximal tubule for
AT1 receptor-dependent effects. In this context, recent studies
showed a crucial role of renal AT1 receptors for sustained
angiotensin II-dependent hypertension (9, 10). Jointly, Arap1
and Atrap therefore may facilitate angiotensin II-dependent
tubular reabsorption and preserve glomerular filtration.
Our data suggest that downregulation of vascular Arap1 by
angiotensin II might be kidney specific, because expression in
the heart and aorta was unchanged, and even increased in the
adrenal gland. Enhanced Arap1 abundance in the adrenal gland
during angiotensin II infusion may contribute to long-term
preservation of angiotensin II-dependent aldosterone release
(4). Further studies are necessary to assess the functional
relevance of Arap1 for AT1 signaling.
In summary, Arap1 is expressed in the renal vasculature of
mice and humans. In vivo and in vitro data suggest that renal
Arap1 expression is suppressed by AT1 receptor activation.
Thus Arap1 may serve as a local modulator of vascular AT1
receptor function and may contribute to adaptations of the renal
vasculature in response to increased levels of circulating an-
giotensin II.
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